About Heterogeneous nuclear ribonucleoproteins C1/C2
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) is a protein
from Homo sapiens identified by UniProt accession
P07910, 306 residues long.
MolForge cross-references it against 0 known binders and
156 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoproteins C1/C2 |
|---|
| UniProt accession | P07910 |
|---|
| Gene | HNRNPC |
|---|
| Organism | Homo sapiens |
|---|
| Length | 306 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (156)
Diseases linked to this target (Open Targets).
- complex neurodevelopmental disorder · score 0.37
- neurodegenerative disease · score 0.36
- C-reactive protein measurement · score 0.29
- total blood protein measurement · score 0.27
- breast adenocarcinoma · score 0.23
- body height · score 0.21
- genetic disorder · score 0.18
- esophageal cancer · score 0.14
- hepatocellular carcinoma · score 0.10
- cancer · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P07910-F1 | alphafold | PREDICTED | 70.38 | — |
Amino-acid sequence (306 residues)
MASNVTNKTD PRSMNSRVFI GNLNTLVVKK SDVEAIFSKY GKIVGCSVHK GFAFVQYVNE RNARAAVAGE DGRMIAGQVL DINLAAEPKV NRGKAGVKRS AAEMYGSVTE HPSPSPLLSS SFDLDYDFQR DYYDRMYSYP ARVPPPPPIA RAVVPSKRQR VSGNTSRRGK SGFNSKSGQR GSSKSGKLKG DDLQAIKKEL TQIKQKVDSL LENLEKIEKE QSKQAVEMKN DKSEEEQSSS SVKKDETNVK MESEGGADDS AEEGDLLDDD DNEDRGDDQL ELIKDDEKEA EEGEDDRDSA NGEDDS
Explore Heterogeneous nuclear ribonucleoproteins C1/C2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets